Recombinant Fusion Proteins

"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Descriptor ID	D011993
MeSH Number(s)	D12.776.828.300
Concept/Terms	Recombinant Fusion Proteins Recombinant Fusion Proteins Proteins, Recombinant Fusion Fusion Proteins, Recombinant Hybrid Proteins, Recombinant Hybrid Proteins, Recombinant Proteins, Recombinant Hybrid Recombinant Hybrid Proteins Chimeric Proteins, Recombinant Chimeric Proteins, Recombinant Proteins, Recombinant Chimeric Recombinant Chimeric Proteins

Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Recombinant Proteins [D12.776.828]
Recombinant Fusion Proteins [D12.776.828.300]

Below are MeSH descriptors whose meaning is related to "Recombinant Fusion Proteins".

Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".

Recombinant Fusion Proteins
CD4 Immunoadhesins
Transcription Activator-Like Effector Nucleases
Zinc Finger Nucleases

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.

Bar chart showing 378 publications over 30 distinct years, with a maximum of 27 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	11	11
1996	1	8	9
1997	1	11	12
1998	1	16	17
1999	0	16	16
2000	0	22	22
2001	0	16	16
2002	1	18	19
2003	1	18	19
2004	0	27	27
2005	1	18	19
2006	0	20	20
2007	2	9	11
2008	0	11	11
2009	6	16	22
2010	4	20	24
2011	3	13	16
2012	2	6	8
2013	2	9	11
2014	2	6	8
2015	2	9	11
2016	3	9	12
2017	3	6	9
2018	3	5	8
2019	2	2	4
2020	3	4	7
2021	2	2	4
2022	0	2	2
2023	0	1	1
2025	2	0	2

Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.

Abdulelah M, Ezenna C, Jenil-Franco A, Jamouss KT, Krishna MM, Joseph M, Chi KY, Dahhan T. Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Vascul Pharmacol. 2025 Sep; 160:107520.

View in: PubMed
Wu QC, Lee J, Swaminathan A, Winward A, Hwang Y, Socolovsky M, Way JC, Klein AM. Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life. Protein Eng Des Sel. 2025 Jan 10; 38.

View in: PubMed
Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, Proud CM, Shieh PB, Tizzano EF, Quijano-Roy S, Desguerre I, Saito K, Faulkner E, Benguerba KM, Raju D, LaMarca N, Sun R, Anderson FA, Finkel RS. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. J Neuromuscul Dis. 2024; 11(2):425-442.

View in: PubMed
Archambault SD, Nichols MM, McCullum JC, Zhang Y, Steinberger EE, Ramsey DJ. Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 Jan 01; 72(Suppl 1):S101-S105.

View in: PubMed
Shaughnessy J, Chabeda A, Tran Y, Zheng B, Nowak N, Steffens C, DeOliveira RB, Gulati S, Lewis LA, Maclean J, Moss JA, Wycoff KL, Ram S. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 2022; 13:975676.

View in: PubMed
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.

View in: PubMed
Kramme C, Plesa AM, Wang HH, Wolf B, Smela MP, Guo X, Kohman RE, Chatterjee P, Church GM. MegaGate: A toxin-less gateway molecular cloning tool. STAR Protoc. 2021 12 17; 2(4):100907.

View in: PubMed
Bettoni S, Maziarz K, Stone MRL, Blaskovich MAT, Potempa J, Bazzo ML, Unemo M, Ram S, Blom AM. Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics in Neisseria gonorrhoeae. Front Immunol. 2021; 12:726801.

View in: PubMed
Ramsey DJ, McCullum JC, Steinberger EE, Zhang Y, Alwreikat AM, Cooper ML, Roh S, Cotran PR. Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022 09; 36(9):1813-1819.

View in: PubMed
Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.

View in: PubMed

People

Explore

Similar Concepts

Top Journals